莲花健康(600186) - 2022 Q1 - 季度财报
LHGLHG(SH:600186)2022-04-29 16:00

Financial Performance - The company's operating revenue for Q1 2022 was ¥417,456,782.99, representing a year-on-year increase of 0.72%[6] - The net profit attributable to shareholders for Q1 2022 was ¥14,652,986.00, showing a significant increase of 32.80% compared to the same period last year[6] - The net cash flow from operating activities reached ¥59,271,724.69, marking a substantial increase of 246.73% year-on-year[6] - The basic earnings per share for Q1 2022 was ¥0.008, unchanged from the previous year[9] - Operating profit for Q1 2022 was CNY 21,374,494.15, up from CNY 19,007,701.82 in Q1 2021, reflecting an increase of approximately 12.5%[27] - Net profit for Q1 2022 reached CNY 15,668,519.37, compared to CNY 12,074,523.10 in Q1 2021, marking a growth of around 30.0%[29] - The net profit attributable to shareholders of the parent company was CNY 14,652,986.00 in Q1 2022, an increase from CNY 11,033,820.63 in Q1 2021, representing a growth of approximately 32.5%[29] - The total comprehensive income for Q1 2022 was CNY 15,665,631.69, compared to CNY 12,074,523.10 in Q1 2021, showing an increase of approximately 30.0%[29] Assets and Liabilities - The total assets at the end of Q1 2022 were ¥2,216,633,686.30, a decrease of 2.08% from the end of the previous year[9] - Total current assets amounted to ¥1,472,214,449.25, a decrease from ¥1,518,116,957.13 as of December 31, 2021, reflecting a decline of approximately 3%[18] - Total assets as of March 31, 2022, were ¥2,216,633,686.30, down from ¥2,263,654,921.95 at the end of 2021, a decrease of about 2.1%[21] - Total current liabilities decreased to ¥1,011,253,556.38 from ¥1,073,941,867.57, reflecting a reduction of approximately 5.8%[21] - The company’s total liabilities decreased to ¥1,755,672,793.43 from ¥1,817,453,832.39, reflecting a decline of approximately 3.4%[21] - Total liabilities amounted to CNY 1,030,876,140.03, a decrease from CNY 1,093,564,451.21 in the previous period, indicating a reduction of about 5.7%[23] - Total equity attributable to shareholders of the parent company was CNY 1,420,481,370.81, up from CNY 1,405,829,828.65, reflecting an increase of approximately 1.0%[23] Cash Flow - Cash inflow from operating activities for Q1 2022 was approximately $487.99 million, an increase from $471.57 million in Q1 2021, representing a growth of about 3.0%[32] - The net cash flow from operating activities for Q1 2022 was approximately $59.27 million, significantly higher than $17.09 million in Q1 2021, marking an increase of about 247.0%[32] - Cash received from tax refunds in Q1 2022 was approximately $12.74 million, compared to $1.94 million in Q1 2021, indicating a growth of about 558.0%[32] - The total cash and cash equivalents at the end of Q1 2022 amounted to approximately $663.18 million, up from $58.07 million at the end of Q1 2021, reflecting a substantial increase[34] - The net increase in cash and cash equivalents for Q1 2022 was approximately $46.25 million, compared to $11.82 million in Q1 2021, indicating a significant improvement[34] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 66,560[12] - The largest shareholder, Wuhu Liantai Investment Management Center, held 10.06% of the shares, totaling 180,509,529 shares[12] Operational Efficiency - The company experienced a significant increase in net profit due to changes in financing structure and a substantial decrease in financial expenses[11] - The company reported a decrease in sales expenses to CNY 16,996,675.14 in Q1 2022 from CNY 25,925,147.69 in Q1 2021, a reduction of about 34.5%[27] - Research and development expenses for Q1 2022 were CNY 1,948,187.29, slightly up from CNY 1,910,415.28 in Q1 2021, indicating a growth of around 2.0%[27] Inventory and Receivables - Accounts receivable decreased to ¥101,052,966.14 from ¥105,517,434.01, indicating a reduction of about 4.4%[18] - Inventory decreased significantly from ¥92,524,544.80 to ¥52,295,267.74, representing a decline of approximately 43.5%[18] Government Support - The company received government subsidies amounting to ¥55,445.59, which are closely related to its normal business operations[11] Product Development - The company has not reported any significant new product developments or market expansions during the reporting period[16]